A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
12 March 2021 | 09:39am
StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests, including lateral flow tests.
The agreement with the DHSC follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate | Company News | Corporate, London Stock Exchange, Regulatory News Headlines Sensyne signs government deal for covid tests study investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
9 February 2021 | 13:58pm
StockMarketWire.com - Sensyne Health has licenced its MagnifEye technology to Excalibur Healthcare Services for use with lateral flow diagnostic tests, including Covid-19.
The MagnifEye system is a smartphone and a web-based app that uses a cloud-based deep learning algorithm to analyse lateral flow tests.
The initial focus will be on use of MagnifEye for Covid-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer and other disease conditions that Excalibur is currently developing.
The Excalibur Covid-19 antigen lateral flow diagnostic test has been approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.